WCN26-6543 DEFINING THE ROLES OF SGLT2IS AND GLP-1 RAS IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES AND OVERWEIGHT/OBESITY: A DELPHI CONSENSUS

Read full text Summarise with VIRAT
Authors: Yehuda Handelsman, Alice Y. Y. Cheng, Gian Paolo Fadini, Pam R. Kushner, Fabrice Bonnet, Paola Fioretto, Takashi Kadowaki, Naresh Kanumilli, Xavier Cos, Thomas Frese, Linong Ji, Peter R Rossing
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) has a global prevalence of >10% and is associated with comorbidities such as type 2 diabetes (T2D) and obesity. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated kidney benefits through pivotal clinical trials and are guideline-directed therapies. However, further clarity is needed on their optimal sequencing in clinical practice. This Delphi panel aimed to establish consensus on the use of these drug classes as foundational (part of first line) versus add-on therapies in adults with CKD and T2D with or without overweight/obesity.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104633–104633
Publication date
25 March 2026
Language
EN